759-P: Glycemic Outcomes over 15 Months with the Omnipod 5 Automated Insulin Delivery System
Authors: CRIEGO AMY B. , CARLSON ANDERS L. , FORLENZA GREGORY P. , BODE BRUCE W. , LEVY CAROL J. , HANSEN DAVID W. , HIRSCH IRL B. , BROWN SUE A. , BERGENSTAL RICHARD M. , SHERR JENNIFER , MEHTA SANJEEV N. , LAFFEL LORI M. , SHAH VIRAL , BHARGAVA ANUJ , WEINSTOCK RUTH S. , MACLEISH SARAH A. , DESALVO DANIEL , JONES THOMAS C. , ALEPPO GRAZIA , BUCKINGHAM BRUCE A. , LY TRANG T. ,   OMNIPOD 5 RESEARCH GROUP
Published: May 2022

Safe and effective use of the Omnipod 5 Automated Insulin Delivery (AID) System was demonstrated in adults and children with type 1 diabetes (T1D) during a 3-mo pivotal study. Longer studies evaluating durability of glycemic benefit of AID systems for &gt;1 year are limited. We present results from a 12-mo extension study for a total of 15mo of system use. In the pivotal study, participants aged 6-70y with T1D≥6mo and A1C&lt;10% used the AID system for 3mo, after 14d of their standard therapy (ST, pump therapy or multiple daily injections) . They were then invited to continue system use in an extension study, with outcomes measured every 3mo. Safety and efficacy endpoints included severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) , and A1C and time in range (TIR, % 70-180 mg/dL) , respectively, during each 3-mo AID interval compared with the ST phase. Most participants (95%) continued into the extension study. At baseline, children (N=110, ages 6-13.9y) and adults (N=114, ages 14-70y) were aged (mean±SD) 10±2y and 37±14y with T1D duration 5±3y and 17±11y, respectively. There were 2 SH and 1 DKA episodes during the 12-mo extension. For both age groups, TIR and A1C improvements were sustained through 15mo of system use compared with ST. The safety and improved glycemic outcomes from the 3-mo pivotal study persisted for an additional 12mo, indicating the potential long-term benefit of the Omnipod 5 System.

Disclosure

A.B.Criego: Advisory Panel; Insulet Corporation, Other Relationship; Medscape, Sanofi, Research Support; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Medtronic. J.Sherr: Advisory Panel; Bigfoot Biomedical, Inc., Cecelia Health, Insulet Corporation, Medtronic, Vertex Pharmaceuticals Incorporated, Consultant; Insulet Corporation, Lexicon Pharmaceuticals, Inc., Research Support; Dexcom, Inc., Insulet Corporation, Jaeb Center for Health Research, JDRF, Medtronic, National Institute of Diabetes and Digestive and Kidney Diseases, Speaker's Bureau; Lilly Diabetes. S.N.Mehta: None. L.M.Laffel: Advisory Panel; Medtronic, Roche Diabetes Care, Consultant; Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompé, Insulet Corporation, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk, Provention Bio, Inc. V.Shah: Advisory Panel; Medscape, Sanofi, Consultant; Dexcom, Inc., Research Support; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk. A.Bhargava: Research Support; Abbott Diabetes, AbbVie Inc., Boehringer Ingelheim International GmbH, Boston Therapeutics, Inc., Covance, Dexcom, Inc., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Insulet Corporation, Kowa Pharmaceuticals America, Inc., Lexicon Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Medtronic, Novo Nordisk, Poxel SA, Quintiles, Sanofi, Senseonics, Tolerion, Inc., Viking Therapeutics, vTv Therapeutics. R.S.Weinstock: Research Support; Boehringer Ingelheim International GmbH, Dexcom, Inc., Diasome, Eli Lilly and Company, Insulet Corporation, Kowa Pharmaceuticals America, Inc., Medtronic, Novo Nordisk, Tandem Diabetes Care, Inc., Tolerion, Inc. S.A.Macleish: Advisory Panel; Insulet Corporation. D.Desalvo: Consultant; Dexcom, Inc., Insulet Corporation, Research Support; Insulet Corporation. T.C.Jones: None. G.Aleppo: Consultant; Insulet Corporation, Research Support; AstraZeneca, Dexcom, Inc., Eli Lilly and Company, Fractyl Health, Inc., Insulet Corporation, Novo Nordisk, Speaker's Bureau; Dexcom, Inc. A.L.Carlson: Advisory Panel; MannKind Corporation, Employee; Bright Health Group, Other Relationship; Medtronic, Research Support; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk, Sanofi, UnitedHealth Group. B.A.Buckingham: Advisory Panel; Arecor, Lilly Diabetes, Medtronic, Other Relationship; Insulet Corporation, Research Support; Insulet Corporation, Lilly Diabetes, Medtronic. T.T.Ly: Employee; Insulet Corporation, Stock/Shareholder; Insulet Corporation. Omnipod 5 research group: n/a. G.P.Forlenza: Advisory Panel; Lilly, Medtronic, Consultant; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Research Support; Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care, Inc. B.W.Bode: Advisory Panel; CeQur SA, MannKind Corporation, Medtronic, Novo Nordisk, Zealand Pharma A/S, Consultant; Bigfoot Biomedical, Inc., Research Support; Abbott, Beta Bionics, Inc., Dexcom, Inc.

Funding

This study was funded by Insulet Corporation.